Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lipiecki, J.
Right arrow Articles by Ponsonnaille, J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Lipiecki, J.
Right arrow Articles by Ponsonnaille, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Which patients with ischaemic heart disease could benefit from cell replacement therapy?

Janusz Lipiecki*, Nicolas Durel and Jean Ponsonnaille

Department of Cardiology, University Hospital, rue Montalembert, 63000 Clermont-Ferrand, France

* Corresponding author. E-mail address: jlipiecki{at}chu-clermontferrand.fr

Recently, cell replacement therapy has been investigated as a new tool in patients with ischaemic heart disease (IHD), who are prone to or with already established systolic dysfunction. Different subsets of stem cells have been used for preventive as well as curative purposes. Although cardiac cell transplantation and cytokine mobilization originally began in clinical trials with the explicit goal of myocardial regeneration, more recently, the emphasis has been focused on remodelling attenuation capacities of this approach. Left ventricular (LV) remodelling is a complex process involving changes in size, shape, and function of the LV, which plays an important role in the development of chronic heart failure after acute myocardial infarction (AMI).

Recently, several studies have improved our knowledge about prevalence, clinical importance, and methods predicting the occurrence of LV remodelling after AMI.

In patients with established LV remodelling, the place of cell replacement therapy is to be assessed in function of recent progresses concerning the selection of patients for revascularization therapy as well as for other surgical and electrical methods.

This article deals with the possibilities of screening of patients with IHD for cell replacement therapy.

Key Words: Cell replacement therapy • Left ventricular remodelling • Heart failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.